enVVeno Medical Corporation announced preliminary findings from a VenoValve health economic study, which indicated that the VenoValve would be a cost-effective treatment option for patients with severe Chronic Venous Insufficiency (CVI). The analysis demonstrated that the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatments.
The study projected that the VenoValve could potentially save $5.9 billion annually in healthcare costs for the approximately 2.5 million U.S. patients with severe CVI who would be candidates for the device. This quantitative benefit highlights the significant value proposition for healthcare systems.
This economic data complements the strong clinical data, making the VenoValve an attractive solution for both patients and payers. The ability to demonstrate cost savings alongside improved patient outcomes is a powerful driver for market penetration upon regulatory approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.